ScioScientific LLC

12/01/2025

Advocates are calling on South Africa to issue a compulsory license for Gilead’s HIV prevention drug, lenacapavir, after the U.S. refused to include the country in a major distribution deal. They argue that leaving South Africa out undermines global HIV‑prevention efforts and that affordable access to breakthrough treatments shouldn’t be limited by politics. Read more on this.

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention treatment.

12/01/2025

Bringing awareness to
Today we honor those we’ve lost, support those living with HIV, and stand together for a future free from stigma and discrimination.
Let’s keep the conversation going.

11/30/2025

Robert F. Kennedy Jr. is warning about thimerosal, a mercury‑based preservative used in some vaccines, despite decades of research showing it’s safe. The concern? His message could fuel vaccine hesitancy around the globe. Read more on this.

Health secretary RFK Jr. wants other countries to ban the use of the preservative thimerosal in vaccines, despite research showing it is a safe ingredient.

11/29/2025

The Trump administration is rolling out a new plan to provide Gilead’s HIV‑prevention drug lenacapavir to some low-income countries, but South Africa, despite having one of the world’s highest HIV burdens, has been left out. Advocates are calling for justice and access. Here's more on this. .

The US has started to provide doses of a Gilead HIV prevention drug to low-income countries, but the program will not include South Africa, officials said.

11/28/2025

A new analysis raises big ethical concerns: many low- and middle-income countries where clinical trials are run don’t actually get access to the approved drugs afterward. It’s a serious gap between testing and sharing the benefits. We need a rethink on global trial equity. Here's more on this.

https://www.statnews.com/pharmalot/2025/11/17/pharma-biotech-clinical-trials-poor-helsinki-ethics/

11/27/2025

A judge has approved a landmark $7 billion settlement between Purdue Pharma (maker of OxyContin) and the Sackler family, who must give up ownership. This could be a turning point in efforts to compensate victims and address the opioid crisis. Read more on this.

A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma’s latest deal to settle thousands of lawsuits over the toll of opioids.

11/26/2025

The biotech world is seriously rethinking mental health treatment: we’re moving past “me‑too” psychiatric drugs and leaning into high-risk, high-reward therapies that target the biology of mental illness. This shift could unlock more effective, groundbreaking treatments for conditions like schizophrenia, a real turning point for mental health innovation. Here's more on this.

A strategic and financial recalibration on psychiatric drug development brings profound implications for investors, insurers, and the health care economy.

11/25/2025

Pfizer is quietly gearing up for a deeper push into digital health, posting a new role to help develop FDA-ready drug–app combinations. A clear sign that the future of medicine is becoming increasingly digital.

In this edition of STAT's Health Tech newsletter: Pfizer hints at its brewing digital health work, and more health tech news.

11/24/2025

GLP-1 weight-loss drugs are opening up a new chapter in health, but many wellness apps aren’t keeping up. Instead of just chasing numbers like VO₂ max or sleep scores, we need platforms that build connection, meaning, and personal agency. Read more on this.

How the tech world can support the weight-loss drug revolution.

11/21/2025

COVID-era telehealth rules allowing the remote prescribing of ADHD stimulants (like Ritalin) and addiction meds (like buprenorphine) have been extended for another year, continuing access for many who depend on virtual care. Read more on this.

For a fourth time, the government avoids making permanent policy on telehealth prescriptions of controlled medications for addiction and ADHD.

11/20/2025

Sports‑betting apps are fueling a public health crisis, especially among young men, with constant access and aggressive marketing leading to risky gambling behaviors. Here's more on this.

Sports betting is more addictive than ever, and millions of young Americans are paying the price.

11/19/2025

The FDA has officially reversed its warning on hormone therapy, a major win for menopause care. This update could reshape how women manage symptoms like hot flashes, bone loss, and more. Here's more on this.

The FDA is reversing a 2003 decision that put a stringent warning on hormone therapy products for menopausal women, saying that the treatments offer heart, brain, and bone health benefits.